Gad Allah, S., Ali–Eldin, Z., Matta, G., Youssef, R. (2023). The Association of Serum Ferritin with Disease Severity in Non-Alcoholic Fatty Liver Disease. The Egyptian Journal of Hospital Medicine, 90(1), 206-212. doi: 10.21608/ejhm.2023.279313
Shaimaa Hussein Gad Allah; Zainab Ahmed Ali–Eldin; George Safwat Matta; Rafik Youssef Awad Youssef. "The Association of Serum Ferritin with Disease Severity in Non-Alcoholic Fatty Liver Disease". The Egyptian Journal of Hospital Medicine, 90, 1, 2023, 206-212. doi: 10.21608/ejhm.2023.279313
Gad Allah, S., Ali–Eldin, Z., Matta, G., Youssef, R. (2023). 'The Association of Serum Ferritin with Disease Severity in Non-Alcoholic Fatty Liver Disease', The Egyptian Journal of Hospital Medicine, 90(1), pp. 206-212. doi: 10.21608/ejhm.2023.279313
Gad Allah, S., Ali–Eldin, Z., Matta, G., Youssef, R. The Association of Serum Ferritin with Disease Severity in Non-Alcoholic Fatty Liver Disease. The Egyptian Journal of Hospital Medicine, 2023; 90(1): 206-212. doi: 10.21608/ejhm.2023.279313
The Association of Serum Ferritin with Disease Severity in Non-Alcoholic Fatty Liver Disease
Internal Medicine & Gastroenterology Department, Faculty of Medicine, Ain Shams University, Egypt
Abstract
Background: It is widely acknowledged that non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the West. It is associated with insulin resistance and frequently coexists with metabolic syndrome symptoms. Ferritin is an acute phase reactant, though, thus its increase in a patient with fatty liver disease's serum could perhaps be a sign of inflammation in addition to disease activity. Objective: The aim of our study was to evaluate the association of serum ferritin with non-alcoholic fatty liver disease in patients with normal and elevated lipid profile. Patients and Methods: The study was cross sectional study, which conducted at Ain Shams University Hospital. This study was conducted on 80 patients. They were divided in to 2 groups as following: Group I included: 40 NAFLD patients with normal lipid profile. Group II included: 40 NAFLD patients with elevated lipid profile. Lipid profile and serum ferritin were done. Results: Our research showed that patients with increased lipid profiles and non-alcoholic fatty liver disease had considerably higher serum ferritin levels than those with normal lipid profiles. However, there was no connection between serum ferritin and the fibrosis score for NAFLD, hepatic steatosis index, or fatty liver index. Conclusion: Serum ferritin may be promising adjuvant inflammatory marker of predication and prognosis in NAFLD patients especially in those with elevated lipid profile. Also, serum ferritin level cannot alone reflect severity of NAFLD.